Radiopharm Theranostics reported positive P1 imaging data for RAD301, with favorable safety, biodistribution and significant tumor uptake in evaluable pancreatic cancer patients. The findings support continued clinical development and the potential use of αvβ6-integrin targeting for pancreatic cancer detection, patient selection and future theranostic applications.

Key Highlights

  • RAD301 showed favorable safety and biodistribution across all dosed subjects.
  • Evaluable pancreatic cancer patients demonstrated significant and selective uptake in metastatic tumors.
  • Low background uptake in the liver, lung and bowel supported clearer distinction between lesions and normal tissue.

RAD301 Shows Selective Pancreatic Tumor Uptake

The results showed favorable safety and biodistribution, as well as significant tumor uptake. Together, these findings support continued clinical development of the radiopharmaceutical.

RAD301 is a peptide-based molecule designed to target αvβ6-integrin, a marker associated with tumor invasion and metastatic growth. In imaging of all evaluable pancreatic cancer patients, the molecule showed significant, selective uptake in metastatic lesions.

RAD301 has previously received Orphan Drug Designation from the FDA. The results also identified low background uptake in the liver, lung and bowel—sites where pancreatic cancer commonly spreads.

Findings Support Continued Clinical Development

The data support αvβ6-integrin as a potential target for future therapeutic development and as a possible theranostic pair. Radiopharm (NASDAQ: RADX) said the findings support advancing RAD301 into further clinical development, including a future imaging trial.

The company also linked the program to potential applications in disease detection, patient selection and future theranostic use. Riccardo Canevari, chief executive and managing director, said the results showed significant and selective uptake in metastatic lesions.

In an announcement dated September 9, 2026, the company said the findings were relevant to a disease with limited imaging and treatment options.